Registered title, quoted from ClinicalTrials.gov
A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Huashan Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06957977, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
WHO pathological types: adenocarcinoma or neuroendocrine tumors;
Inclusion criterion 3
Patients diagnosed with advanced gastric cancer (stage IV according to the AJCC 8th edition, including locally advanced unresectable gastric cancer [stage IVa] and gastric cancer with distant metastasis [stage IVb]; Borrmann classification types I, II, or III) who are deemed ineligible for surgical resection or unable to tolerate surgery, and meet the indications for first-line therapy with sintilimab combined with fluoropyrimidine- and platinum-based chemotherapy;
Inclusion criterion 1
Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
Inclusion criterion 10
Hematological criteria: hemoglobin (Hgb) ≥70 g/L; absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet count (PLT) ≥80×10⁹/L;
Inclusion criterion 7
Patients with infectious diseases (such as HIV, syphilis, or active tuberculosis);
Exclusion criterion 2
Negative pregnancy test for women of childbearing potential;
Inclusion criterion 9
Pregnant or breastfeeding women, or women planning to become pregnant within six months;
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06957977, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Patients diagnosed with advanced gastric cancer (stage IV according to the AJCC 8th edition, including locally advanced unresectable gastric cancer [stage IVa] and gastric cancer with distant metastasis [stage IVb]; Borrmann classification types I, II, or III) who are deemed ineligible for surgical resection or unable to tolerate surgery, and meet the indications for first-line therapy with sintilimab combined with fluoropyrimidine- and platinum-based chemotherapy;
- Age ≥18 years;
- WHO pathological types: adenocarcinoma or neuroendocrine tumors;
- Physician-assessed estimated life expectancy greater than 3 months, with distant metastases considered controllable;
- Maximum diameter of the primary tumor ≤6 cm;
- Adequate major organ function, defined as:① Liver function: ALT and AST ≤ 2.5 times the positive range, total bilirubin ≤ 2.0mg/dL; ② Renal function: creatinine clearance ≥ 40mL/min calculated using the EPI formula;
- Hematological criteria: hemoglobin (Hgb) ≥70 g/L; absolute neutrophil count (ANC) ≥1.5×10⁹/L; platelet count (PLT) ≥80×10⁹/L;
- Coagulation function: prothrombin time (PT) and activated partial thromboplastin time (APTT) both <2 times the normal value;
- Negative pregnancy test for women of childbearing potential;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
- Signed informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding women, or women planning to become pregnant within six months;
- Patients with infectious diseases (such as HIV, syphilis, or active tuberculosis);
- Patients with active hepatitis B or hepatitis C infection;
- Patients with other concurrent primary malignancies;
- Patients who have participated in another clinical trial within the past month;
- Patients who have taken antiplatelet or anticoagulant medications within the past week;
- Patients with gastric cancer complicated by active bleeding;
- Patients with massive ascites (ascites volume ≥3000 mL);
- Patients with cardia obstruction or pyloric obstruction;
- Patients with active infections or autoimmune diseases;
- Patients deemed unsuitable for treatment by the investigator for any other reason.
Quoted from ClinicalTrials.gov, NCT06957977, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06957977, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.